DRUG: Darunavir, cobicistat, emtricitabine and tenofovir alafenamide Help
Entry Name Darunavir, cobicistat, emtricitabine and tenofovir alafenamide;
Product Component (Darunavir [DR:
D03656 ] | Darunavir ethanolate [DR:
D06478 ]), Cobicistat [DR:
D09881 ], Emtricitabine [DR:
D01199 ], (Tenofovir alafenamide [DR:
D10428 ] | Tenofovir alafenamide fumarate [DR:
D10605 ])
Class AntiviralDG03107 Anti-HIV agentDG01644 CYP2D6 substrateDG01633 CYP3A/CYP3A4 substrateDG01645 CYP2D6 inhibitorDG02852 CYP3A/CYP3A4 inhibitorDG01665 ABCB1 substrateDG03001 CTSA substrateDG01622 ABCB1 inhibitorDG02862 ABCG2 inhibitorDG02865 SLCO1B1 inhibitorDG02907 SLCO1B3 inhibitor Remark Therapeutic category: 6250
Efficacy Antiviral
Disease Comment Darunavir is a substrate of CYP3A; it is also an inhibitor of CYP3A, CYP2D6 and P-gp.
Target HIV protease [KO:
K22599 ]
HIV-1 reverse transcriptase [KO:
K24802 ]
Pathway Metabolism Interaction CYP inhibition: CYP3A [HSA:
1576 1577 1551 ], CYP2D6 [HSA:
1565 ]
Transporter inhibition: ABCB1 [HSA:
5243 ], ABCG2 [HSA:
9429 ], SLCO1B1 [HSA:
10599 ], SLCO1B3 [HSA:
28234 ]
DDI search Brite Anatomical Therapeutic Chemical (ATC) classification [BR:br08303 ]br08302 ]br08301 ]br08330 ]br08332 ]br08307 ]br08329.html ]br08309.html ] BRITE hierarchy Other DBs LinkDB All DBs
» Japanese version » Back 